These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2498 related items for PubMed ID: 17438091

  • 1. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.
    Cancer; 2010 Mar 15; 116(6):1431-9. PubMed ID: 20131351
    [Abstract] [Full Text] [Related]

  • 3. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 15; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep 15; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 5. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.
    Breast Cancer Res Treat; 2008 Oct 15; 111(3):411-7. PubMed ID: 17968656
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM, Lowe KA, Atwood M, Beatty JD.
    Breast J; 2010 Oct 15; 16(4):362-8. PubMed ID: 20443786
    [Abstract] [Full Text] [Related]

  • 7. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.
    Breast Cancer Res Treat; 2010 Jan 15; 119(1):119-26. PubMed ID: 19669409
    [Abstract] [Full Text] [Related]

  • 8. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar 15; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
    Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H, Uchida K.
    Oncol Rep; 2009 Feb 15; 21(2):413-7. PubMed ID: 19148516
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.
    Breast Cancer Res Treat; 2012 Feb 12; 131(3):827-36. PubMed ID: 21472434
    [Abstract] [Full Text] [Related]

  • 16. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.
    Breast Cancer; 2009 Feb 12; 16(4):260-7. PubMed ID: 19701681
    [Abstract] [Full Text] [Related]

  • 17. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.
    J Clin Oncol; 2006 Jul 01; 24(19):3019-25. PubMed ID: 16754938
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
    J Clin Oncol; 2007 Nov 20; 25(33):5194-202. PubMed ID: 17954712
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 125.